Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Bionor

    - PMLiVE

    Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

    An estimated 1.2 million people in the US are currently living with the virus

    - PMLiVE

    Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

    More than 100 people in the US were diagnosed with HIV every day in 2023

    - PMLiVE

    Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

    The companies will aim to discover new antibody-based therapeutics for cancer

    - PMLiVE

    Cultivating Interest in Infectious Disease Education at ID Week 2024

    IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

    Medscape Education

    - PMLiVE

    Innovative Trials Announces New Charity Partnerships

    Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

    Innovative Trials

    - PMLiVE

    Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

    “I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

    Medscape Education

    - PMLiVE

    Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

    The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

    tijana being interviewed

    Envision Analogue – An Introduction

    Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

    Genesis Research Group

    - PMLiVE

    Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

    STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

    - PMLiVE

    New technique enables study of immune response to cancer using archived tissue samples

    FUME-TCRseq was shown to successfully read formalin-fixed paraffin-embedded tissue samples

    - PMLiVE

    Gilead and Merus announce oncology partnership worth over $1.5bn

    The companies will aim to discover dual tumour-associated antigens targeting trispecific antibodies

    - PMLiVE

    Researchers develop screening tool to investigate mechanisms behind multiple diseases

    The technique will assess genetic changes in cells behind cancer, autoimmunity and neurodegeneration

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links